BofA raises Ligand Pharma stock price target on royalty growth

BofA raised its Ligand Pharmaceuticals (LGND) price target to $388 from $266 (Buy) citing strong 2025 momentum and continued earnings growth upside from the XOMA royalty deal. Revenue rose 51% to $274M over the last 12 months, and the stock is up 42% since March (157% over the past year), though InvestingPro flags it as overvalued versus fair value. The company also completed a $700M convertible notes offering (net proceeds ~$678.2M) and amended its XOMA merger agreement to include XOMA Royalty Holdings, with Stifel concurrently lifting its target to $332 from $255.

Analysis

LGND’s market debate is less about this quarter’s reported growth and more about whether management can turn a larger, cheaper capital base into ROIC above its cost of equity. That is a real advantage if the balance sheet is used to source scarce royalty assets, but it also means the stock is increasingly underwriting a pipeline of future deals rather than current cash flow; that usually merits a discount, not a premium, once the easy rerate has happened.

The near-term overhang is the convert stack and the associated hedge flow. A 0% coupon converts into latent dilution and can cap upside on rallies, especially if the stock is already extended and the investor base is momentum-driven; in practice, this can keep implied vol elevated while making incremental upside harder to sustain unless there is an earnings beat plus a fresh acquisition thesis. Over the next 1-3 months, the key catalyst is whether the acquired royalty pool actually lifts recurring revenue per share faster than G&A and integration drag.

Contrarian view: the market may be overestimating how quickly a larger royalty platform compounds while underestimating how unforgiving the multiple becomes when growth is financially engineered rather than organically scarce. If execution is merely solid, the stock can stagnate even with bullish broker targets; the cleaner expression is to own the highest-quality royalty platform or wait for a post-event reset rather than chase LGND at an all-time high. A failure signal would be any guidance that shows revenue growth decelerating while share count and financing costs move up, because that would expose the story as dilution-assisted rather than self-funding.

Key Decisions for Investors

• Do not chase LGND after the rerating; if already long, trim into strength or hedge with a 1-3 month LGND put spread (for example, ~10-15% OTM) into the next earnings/update cycle. Falsifier: management shows immediate accretive deployment of cash plus upward EPS guidance, not just revenue growth.
• Pair trade: long RPRX / short LGND for the next 1-3 months to express preference for the more scaled royalty platform versus the more deal-dependent, dilution-sensitive name. Risk/reward improves if LGND remains near highs while borrow/convert hedging keeps pressure on upside.
• If you want exposure to the thesis, wait for a pullback or post-close consolidation before initiating any long in LGND; the better entry is a 5-8% retrace with no fundamental deterioration. Falsifier: sustained closes above recent highs on expanding volume with no follow-through sell pressure from convert hedging.
• Monitor XOMA only as a special-situation read-through, not a standalone long; the merger lens can help estimate whether the acquired assets are truly additive or just balance-sheet capacity absorption. If the combined model does not show faster per-share cash generation in the next quarter, fade the premium multiple.